Jason Z Li, Meredith M Njus, Connor P Oates, Tania A Vora, Ajay Kadakkal, Nana Afari-Armah, Rachel M Barish, Farooq H Sheikh
{"title":"野生型转甲状腺素型心脏淀粉样变黑人患者的特点和预后。","authors":"Jason Z Li, Meredith M Njus, Connor P Oates, Tania A Vora, Ajay Kadakkal, Nana Afari-Armah, Rachel M Barish, Farooq H Sheikh","doi":"10.1016/j.carrev.2025.05.006","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The clinical characteristics and outcomes of Black patients with wild type transthyretin cardiac amyloidosis (ATTRwt-CA) are not well described in the literature.</p><p><strong>Methods: </strong>We conducted a single center retrospective cohort study of 186 patients with cardiac amyloidosis, of which 62 had ATTRwt-CA, diagnosed at our institution between 2/2010 and 4/2023. We compared clinical, laboratory, electrocardiographic, and echocardiographic characteristics between Black and non-Black ATTRwt-CA patients. Our primary outcome of interest was all cause mortality.</p><p><strong>Results: </strong>Of the 62 patients with ATTRwt-CA, 19 patients self-identified as Black. Black ATTRwt-CA patients had higher rates of chronic kidney disease (63.2 % vs 23.3 %; p = 0.002), lower glomerular filtration rate (50.8 ± 18.0 vs 63.3 ± 18.4; p = 0.019), and lower rates of carpal tunnel syndrome (36.8 % vs 67.4 %; p = 0.024). There were no significant differences in disease stage (p = 0.058), frequency of NYHA III or IV symptoms (35.3 % vs 35.5 %; p = 0.990), or LVEF (41.2 ± 17.1 vs 49.1 ± 13.2; p = 0.074) at the time of CA diagnosis. Black ATTRwt-CA patients demonstrated higher rates of mortality on both univariate (HR: 5.52; CI 2.05-14.81; p = 0.001) and multivariate (HR: 4.85; CI 1.53-15.41; p = 0.007) Cox regression analysis.</p><p><strong>Conclusion: </strong>Black patients with ATTRwt-CA demonstrate phenotypic differences and worse survival compared to non-Black patients. The reasons underlying this survival difference warrant further investigation.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Characteristics and outcomes of Black patients with wild type transthyretin cardiac amyloidosis.\",\"authors\":\"Jason Z Li, Meredith M Njus, Connor P Oates, Tania A Vora, Ajay Kadakkal, Nana Afari-Armah, Rachel M Barish, Farooq H Sheikh\",\"doi\":\"10.1016/j.carrev.2025.05.006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The clinical characteristics and outcomes of Black patients with wild type transthyretin cardiac amyloidosis (ATTRwt-CA) are not well described in the literature.</p><p><strong>Methods: </strong>We conducted a single center retrospective cohort study of 186 patients with cardiac amyloidosis, of which 62 had ATTRwt-CA, diagnosed at our institution between 2/2010 and 4/2023. We compared clinical, laboratory, electrocardiographic, and echocardiographic characteristics between Black and non-Black ATTRwt-CA patients. Our primary outcome of interest was all cause mortality.</p><p><strong>Results: </strong>Of the 62 patients with ATTRwt-CA, 19 patients self-identified as Black. Black ATTRwt-CA patients had higher rates of chronic kidney disease (63.2 % vs 23.3 %; p = 0.002), lower glomerular filtration rate (50.8 ± 18.0 vs 63.3 ± 18.4; p = 0.019), and lower rates of carpal tunnel syndrome (36.8 % vs 67.4 %; p = 0.024). There were no significant differences in disease stage (p = 0.058), frequency of NYHA III or IV symptoms (35.3 % vs 35.5 %; p = 0.990), or LVEF (41.2 ± 17.1 vs 49.1 ± 13.2; p = 0.074) at the time of CA diagnosis. Black ATTRwt-CA patients demonstrated higher rates of mortality on both univariate (HR: 5.52; CI 2.05-14.81; p = 0.001) and multivariate (HR: 4.85; CI 1.53-15.41; p = 0.007) Cox regression analysis.</p><p><strong>Conclusion: </strong>Black patients with ATTRwt-CA demonstrate phenotypic differences and worse survival compared to non-Black patients. The reasons underlying this survival difference warrant further investigation.</p>\",\"PeriodicalId\":47657,\"journal\":{\"name\":\"Cardiovascular Revascularization Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-05-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular Revascularization Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.carrev.2025.05.006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Revascularization Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.carrev.2025.05.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
背景:黑人野生型转甲状腺素型心脏淀粉样变性(ATTRwt-CA)患者的临床特征和预后在文献中没有很好的描述。方法:我们对186例心脏淀粉样变性患者进行了单中心回顾性队列研究,其中62例为attrt - ca,于2010年2月至2023年4月在我院诊断。我们比较了黑人和非黑人attrt - ca患者的临床、实验室、心电图和超声心动图特征。我们感兴趣的主要结局是全因死亡率。结果:62例attrt - ca患者中,有19例自认为为Black。黑色attrt - ca患者的慢性肾脏疾病发生率更高(63.2% vs 23.3%;P = 0.002),肾小球滤过率较低(50.8±18.0 vs 63.3±18.4;P = 0.019),腕管综合征发生率较低(36.8% vs 67.4%;p = 0.024)。两组在疾病分期(p = 0.058)、出现NYHA III或IV症状的频率(35.3% vs 35.5%;p = 0.990),或LVEF(41.2±17.1 vs 49.1±13.2;p = 0.074)。黑色attrt - ca患者在两项单因素上均表现出较高的死亡率(HR: 5.52;可信区间2.05 - -14.81;p = 0.001)和多变量(HR: 4.85;可信区间1.53 - -15.41;p = 0.007) Cox回归分析。结论:与非黑人患者相比,黑人患者attrt - ca表现出表型差异和更差的生存率。这种生存差异背后的原因值得进一步调查。
Characteristics and outcomes of Black patients with wild type transthyretin cardiac amyloidosis.
Background: The clinical characteristics and outcomes of Black patients with wild type transthyretin cardiac amyloidosis (ATTRwt-CA) are not well described in the literature.
Methods: We conducted a single center retrospective cohort study of 186 patients with cardiac amyloidosis, of which 62 had ATTRwt-CA, diagnosed at our institution between 2/2010 and 4/2023. We compared clinical, laboratory, electrocardiographic, and echocardiographic characteristics between Black and non-Black ATTRwt-CA patients. Our primary outcome of interest was all cause mortality.
Results: Of the 62 patients with ATTRwt-CA, 19 patients self-identified as Black. Black ATTRwt-CA patients had higher rates of chronic kidney disease (63.2 % vs 23.3 %; p = 0.002), lower glomerular filtration rate (50.8 ± 18.0 vs 63.3 ± 18.4; p = 0.019), and lower rates of carpal tunnel syndrome (36.8 % vs 67.4 %; p = 0.024). There were no significant differences in disease stage (p = 0.058), frequency of NYHA III or IV symptoms (35.3 % vs 35.5 %; p = 0.990), or LVEF (41.2 ± 17.1 vs 49.1 ± 13.2; p = 0.074) at the time of CA diagnosis. Black ATTRwt-CA patients demonstrated higher rates of mortality on both univariate (HR: 5.52; CI 2.05-14.81; p = 0.001) and multivariate (HR: 4.85; CI 1.53-15.41; p = 0.007) Cox regression analysis.
Conclusion: Black patients with ATTRwt-CA demonstrate phenotypic differences and worse survival compared to non-Black patients. The reasons underlying this survival difference warrant further investigation.
期刊介绍:
Cardiovascular Revascularization Medicine (CRM) is an international and multidisciplinary journal that publishes original laboratory and clinical investigations related to revascularization therapies in cardiovascular medicine. Cardiovascular Revascularization Medicine publishes articles related to preclinical work and molecular interventions, including angiogenesis, cell therapy, pharmacological interventions, restenosis management, and prevention, including experiments conducted in human subjects, in laboratory animals, and in vitro. Specific areas of interest include percutaneous angioplasty in coronary and peripheral arteries, intervention in structural heart disease, cardiovascular surgery, etc.